The U.S. general anesthesia drugs market is poised to reach USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020.
Seattle, WA -- (SBWIRE) -- 07/03/2017 -- The report "European Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home care Setting) - Forecast to 2020", provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the European Injectable Drug Delivery Market along with estimates and forecasts of the revenue and market share analysis. The U.S. general anesthesia drugs market is poised to reach USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020.
Browse 230 market data tables and 43 figures spread through 247 pages and in-depth TOC on "European Injectable Drug Delivery Market"
Early buyers will receive 10% customization on reports.
Injectable drug delivery offers a promising alternative for the delivery of drugs that are ineffective when administered orally. Injectable drug delivery is aimed to maximize patient compliance and reduce the frequency of dosage administration without compromising the effectiveness of the treatment.
Get The PDF Brochure For This Report@
The report segments the European Injectable Drug Delivery Market on the basis of types, therapeutic applications, usage patterns, modes of administration, end users, and regions. On the basis of type, the formulations segment is expected to account for the largest share in 2015, closely followed by the devices segment. The formulations segment is expected to grow at the highest CAGR during the forecast period, owing to the rising prevalence of chronic diseases, increase in demand of self-injection devices, growth of the biologics market, technological advancements, emphasis on innovation of formulations, and benefits such high efficacy and reduced side effects offered by formulations. The formulations market is further segmented into conventional drug delivery formulations, novel drug delivery formulations, and long-acting injection formulations. The devices market is further segmented into conventional injection devices, self-injections, and other devices.
Ask for Discount on this Report@
On the basis of therapeutic application, the European Injectable Drug Delivery Market is segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other therapeutic applications. On the basis of usage pattern, the market is segmented into curative care, immunization, and others.
On the basis of mode of administration, the European Injectable Drug Delivery Market is segmented into skin, organs, central nervous system, and circulatory/musculoskeletal system. On the basis of end user, the market is segmented into hospitals/clinics, home care settings, research laboratories, pharma and biotech companies, and other end users.
Geographically, the market is dominated by Germany, followed by France. Germany is expected to account for the largest share of the European Injectable Drug Delivery Market in 2015, with the highest growth rate during the forecast period.
Key players in the European Injectable Drug Delivery Market include Becton, Dickinson and Company (U.S.), Baxter International Inc. (U.S.), Gerresheimer AG (Germany), Pfizer Inc. (U.S.), Schott AG (Germany), Sandoz,(Germany) Teva Pharmaceutical Industries Ltd. (Israel), and Eli Lilly and Company (U.S.).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States